What's Happening?
The European Medicines Agency's (EMA) human medicines committee has recommended the approval of Amgen's bispecific T-cell engager (BiTE), Imdylltra, for use as a second-line treatment for extensive-stage small cell lung cancer (ES-SCLC). Imdylltra, also
known as tarlatamab, targets the DLL3 protein on cancer cells and the CD3 antigen on T cells, thereby activating the immune system to attack the tumor. This approval comes after the drug was first approved in the U.S. nearly two years ago and in the UK over a year ago. The decision is based on the phase 3 DeLLphi-304 study, which demonstrated that Imdylltra reduced the risk of death by 40% and significantly extended median overall survival by more than five months compared to standard second-line chemotherapy for ES-SCLC.
Why It's Important?
The approval of Imdylltra in the EU is significant as it introduces a new treatment option for patients with ES-SCLC, a condition with limited therapeutic options. The drug's ability to target DLL3, a protein found in the majority of SCLC tumors but rarely in healthy cells, represents a targeted approach that could improve patient outcomes. The approval is expected to enhance Amgen's market presence in oncology, with Imdylltra already becoming a standard of care in the U.S. and generating substantial sales. This development could lead to increased competition in the oncology market, potentially driving further innovation and research in cancer treatments.
What's Next?
Following the EMA's recommendation, Imdylltra is expected to be rolled out across the EU, providing a new treatment option for patients with ES-SCLC. Amgen may focus on expanding its market share in Europe and potentially exploring further applications of the BiTE technology in other cancer types. The approval could also prompt other pharmaceutical companies to invest in similar targeted therapies, potentially leading to new collaborations and advancements in cancer treatment.
